Literature DB >> 19953623

Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck.

Sung Kim1, Michael Eleff, Nicos Nicolaou.   

Abstract

BACKGROUND: Head and neck cutaneous squamous cell carcinoma (SCC) metastatic to lymph nodes is commonly treated with surgery plus radiotherapy.
METHODS: We present the case of a 92-year-old man with cutaneous SCC metastatic to the neck (7 cm) who was treated with primary cetuximab and has had a durable complete response for 7 months. Because of his age, comorbidities, and unresectable neck lymphadenopathy, he received primary cetuximab. He received a 400 mg/m(2) loading dose and a 250 mg/m(2) weekly dose for 3 months and then had to discontinue as a result of other unrelated medical issues.
RESULTS: The patient had a complete response by 6 weeks. Seven months after discontinuing cetuximab, he continues to have a complete response.
CONCLUSIONS: Primary cetuximab for cutaneous SCC metastatic to lymph nodes is an area that bears further investigation because of its apparent efficacy and excellent toxicity profile.
Copyright © 2009 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 19953623     DOI: 10.1002/hed.21299

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  8 in total

Review 1.  Developments in the treatment of locally advanced and metastatic squamous cell carcinoma of the skin: a rising unmet need.

Authors:  Paul Palyca; Vadim P Koshenkov; Janice M Mehnert
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

2.  Concomitant cetuximab and radiation therapy: A possible promising strategy for locally advanced inoperable non-melanoma skin carcinomas.

Authors:  Giuseppina Della Vittoria Scarpati; Francesco Perri; Salvatore Pisconti; Giuseppe Costa; Filippo Ricciardiello; Salvatore Del Prete; Alberto Napolitano; Marco Carraturo; Salvatore Mazzone; Raffaele Addeo
Journal:  Mol Clin Oncol       Date:  2016-01-27

3.  Cutaneous squamous cell carcinoma of the head and neck.

Authors:  Vivek V Gurudutt; Eric M Genden
Journal:  J Skin Cancer       Date:  2011-02-21

4.  Outcomes of recurrent head and neck cutaneous squamous cell carcinoma.

Authors:  Nichole R Dean; Larissa Sweeny; J Scott Magnuson; William R Carroll; Daniel Robinson; Renee A Desmond; Eben L Rosenthal
Journal:  J Skin Cancer       Date:  2011-06-09

Review 5.  Epidermal Growth Factor Receptor's Function in Cutaneous Squamous Cell Carcinoma and Its Role as a Therapeutic Target in the Age of Immunotherapies.

Authors:  Priscila Oliveira de Lima; Shannon Joseph; Benedict Panizza; Fiona Simpson
Journal:  Curr Treat Options Oncol       Date:  2020-02-03

6.  Combined cetuximab and volumetric modulated arc-radiotherapy in advanced recurrent squamous cell carcinoma of the scalp.

Authors:  Uwe Wollina; Andreas Schreiber; Knut Merla; Gunter Haroske
Journal:  Dermatol Reports       Date:  2011-12-13

7.  Squamous cell carcinomas of the skin responsive to erlotinib: 5 cases.

Authors:  William L Read; Kevin T Brumund; Robert A Weisman; Angel Q Nguyen
Journal:  JAAD Case Rep       Date:  2015-05-25

Review 8.  Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer.

Authors:  Uwe Wollina; Georgi Tchernev; Torello Lotti
Journal:  Open Access Maced J Med Sci       Date:  2017-12-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.